Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Targeted therapy tucatinib improves survival in people with HER2-positive breast cancer that has spread to the brain.
Finding an effective alternative to multi-agent chemotherapy for patients with high-risk breast cancer is a priority.
Although this subtype is associated with a favorable five-year relative survival rate, there is a risk of recurrence years after treatment.
This meta-analysis of residual cancer burden provides real-world evidence of how patients are responding to neoadjuvant treatments.
Keytruda improves response rates for hard-to-treat breast cancer, but Tecentriq falls short.
New targeted therapy improves survival in people with metastatic HER2-positive breast cancer.
The researchers found that women assigned to anastrozole were 50 percent less likely to have developed breast cancer.
A study looked at circulating tumor DNA as a biomarker for health outcomes among women with triple-negative breast cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.